Clinical Ovarian Cancer
Latest Publications

TOTAL DOCUMENTS

113

(FIVE YEARS 0)

H-INDEX

(FIVE YEARS 0)

Published By Elsevier

1941-4404, 1941-4390

Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords

CON: Therapy for a Patient With Platinum–Resistant/Refractory Ovarian Cancer Should Not be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay

Clinical Ovarian Cancer ◽

10.1016/j.cloc.2012.02.003 ◽

2011 ◽

Vol 4 (2) ◽

pp. 57-61

Author(s):

John Farley ◽

Michael J. Birrer

Keyword(s):

Ovarian Cancer ◽

Drug Sensitivity ◽

Resistant Refractory ◽

Platinum Resistant

Download Full-text

CON: Patients With Metastatic/Recurrent Cervical Cancer Should Not be Treated With Cisplatin Plus Paclitaxel

Clinical Ovarian Cancer ◽

10.1016/j.cloc.2012.02.015 ◽

2011 ◽

Vol 4 (2) ◽

pp. 94-96

Author(s):

J. Tate Thigpen

Keyword(s):

Cervical Cancer ◽

Recurrent Cervical Cancer

Download Full-text

CON: Not All Patients With Serous and Clear Cell Carcinomas of the Endometrium Should Receive Chemotherapy as Part of Their Treatment

Clinical Ovarian Cancer ◽

10.1016/j.cloc.2012.02.019 ◽

2011 ◽

Vol 4 (2) ◽

pp. 111-113

Author(s):

Eric L. Eisenhauer

Keyword(s):

Clear Cell

Download Full-text

CON: Patients at High Risk for Ovarian Cancer Should Not Undergo Routine Screening

Clinical Ovarian Cancer ◽

10.1016/j.cloc.2012.02.013 ◽

2011 ◽

Vol 4 (2) ◽

pp. 86-89

Author(s):

Thomas P. McNally ◽

Michael J. Birrer

Keyword(s):

Ovarian Cancer ◽

High Risk ◽

Routine Screening

Download Full-text

CON: Systemic Therapy for All Endometrial Carcinomas Should Not be Paclitaxel Plus Carboplatin

Clinical Ovarian Cancer ◽

10.1016/j.cloc.2012.02.017 ◽

2011 ◽

Vol 4 (2) ◽

pp. 101-105

Author(s):

J. Tate Thigpen

Keyword(s):

Systemic Therapy ◽

Endometrial Carcinomas

Download Full-text

PRO: Secondary Surgical Debulking is an Acceptable Option in Patients With Recurrent Platinum-Sensitive Ovarian Cancer

Clinical Ovarian Cancer ◽

10.1016/j.cloc.2012.02.010 ◽

2011 ◽

Vol 4 (2) ◽

pp. 77-79

Author(s):

Christa I. Nagel ◽

Matthew J. Carlson ◽

Larry J. Copeland

Keyword(s):

Ovarian Cancer ◽

Platinum Sensitive ◽

Surgical Debulking

Download Full-text

Clinical Ovarian Cancer ◽

10.1016/s1941-4390(12)00025-6 ◽

2011 ◽

Vol 4 (2) ◽

pp. A2-A3

Download Full-text

CON: Patients With Recurrent Ovarian Carcinoma Should Not be Treated With Antiangiogenic Agents in Combination With Chemotherapy

Clinical Ovarian Cancer ◽

10.1016/j.cloc.2012.02.009 ◽

2011 ◽

Vol 4 (2) ◽

pp. 74-76

Author(s):

Paul Sabbatini

Keyword(s):

Ovarian Carcinoma ◽

Antiangiogenic Agents

Download Full-text

CON: Secondary Surgical Debulking is Not an Acceptable Option in Patients With Recurrent Platinum-Sensitive Ovarian Cancer

Clinical Ovarian Cancer ◽

10.1016/j.cloc.2012.02.011 ◽

2011 ◽

Vol 4 (2) ◽

pp. 80-82

Author(s):

J. Tate Thigpen

Keyword(s):

Ovarian Cancer ◽

Platinum Sensitive ◽

Surgical Debulking

Download Full-text

PRO: Patients With Metastatic/Recurrent Cervical Cancer Should be Treated With Cisplatin Plus Paclitaxel

Clinical Ovarian Cancer ◽

10.1016/j.cloc.2012.02.014 ◽

2011 ◽

Vol 4 (2) ◽

pp. 90-93 ◽

Cited By ~ 4

Author(s):

Krishnansu S. Tewari

Keyword(s):

Cervical Cancer ◽

Recurrent Cervical Cancer

Download Full-text

Clinical Ovarian Cancer
Latest Publications

TOTAL DOCUMENTS

H-INDEX

Published By Elsevier

CON: Therapy for a Patient With Platinum–Resistant/Refractory Ovarian Cancer Should Not be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay

CON: Patients With Metastatic/Recurrent Cervical Cancer Should Not be Treated With Cisplatin Plus Paclitaxel

CON: Not All Patients With Serous and Clear Cell Carcinomas of the Endometrium Should Receive Chemotherapy as Part of Their Treatment

CON: Patients at High Risk for Ovarian Cancer Should Not Undergo Routine Screening

CON: Systemic Therapy for All Endometrial Carcinomas Should Not be Paclitaxel Plus Carboplatin

PRO: Secondary Surgical Debulking is an Acceptable Option in Patients With Recurrent Platinum-Sensitive Ovarian Cancer

Table of Contents

CON: Patients With Recurrent Ovarian Carcinoma Should Not be Treated With Antiangiogenic Agents in Combination With Chemotherapy

CON: Secondary Surgical Debulking is Not an Acceptable Option in Patients With Recurrent Platinum-Sensitive Ovarian Cancer

PRO: Patients With Metastatic/Recurrent Cervical Cancer Should be Treated With Cisplatin Plus Paclitaxel

Export Citation Format

Clinical Ovarian CancerLatest Publications

TOTAL DOCUMENTS

H-INDEX

Published By Elsevier

CON: Therapy for a Patient With Platinum–Resistant/Refractory Ovarian Cancer Should Not be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay

CON: Patients With Metastatic/Recurrent Cervical Cancer Should Not be Treated With Cisplatin Plus Paclitaxel

CON: Not All Patients With Serous and Clear Cell Carcinomas of the Endometrium Should Receive Chemotherapy as Part of Their Treatment

CON: Patients at High Risk for Ovarian Cancer Should Not Undergo Routine Screening

CON: Systemic Therapy for All Endometrial Carcinomas Should Not be Paclitaxel Plus Carboplatin

PRO: Secondary Surgical Debulking is an Acceptable Option in Patients With Recurrent Platinum-Sensitive Ovarian Cancer

Table of Contents

CON: Patients With Recurrent Ovarian Carcinoma Should Not be Treated With Antiangiogenic Agents in Combination With Chemotherapy

CON: Secondary Surgical Debulking is Not an Acceptable Option in Patients With Recurrent Platinum-Sensitive Ovarian Cancer

PRO: Patients With Metastatic/Recurrent Cervical Cancer Should be Treated With Cisplatin Plus Paclitaxel

Clinical Ovarian Cancer
Latest Publications